Elagolix as GnRH antagonist in controlled ovarian stimulation for intrauterine insemination

Sadia Afrin Munmun; Nighat Sultana; Mahamuda Yasmin; Dilruba Akhter; Shakeela Ishrat

doi:10.18203/2320-1770.ijrcog20242785

Authors

Sadia Afrin Munmun Department of Reproductive Endocrinology and Infertility, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
Nighat Sultana Department of Reproductive Endocrinology and Infertility, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
Mahamuda Yasmin Department of Reproductive Endocrinology and Infertility, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
Dilruba Akhter Department of Reproductive Endocrinology and Infertility, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
Shakeela Ishrat Department of Reproductive Endocrinology and Infertility, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh https://orcid.org/0000-0002-8568-0417

DOI:

https://doi.org/10.18203/2320-1770.ijrcog20242785

Keywords:

GnRH antagonists, Elagolix, Intrauterine insemination, Ovarian hyperstimulation

Abstract

Background: Controlled ovarian stimulation with gonadotropins may be complicated by premature luteinizing hormone surge and premature luteinization. Premature LH surge and premature luteinization can be inhibited by GnRH antagonists so that gonadotropin stimulation can be extended, enabling the appropriate development of more than one follicle. Elagolix is an oral GnRH antagonist used in treatment of endometriosis. Elagolix, like injectable GnRH antagonists, may be applied for preventing premature luteinization. Objective was to compare the effects of elagolix with no elagolix on preventing premature luteinization in ovarian stimulation with intrauterine insemination, on the day of trigger.

Methods: This quasi-experimental study was conducted on a total of 60 infertile women selected for ovarian stimulation and intrauterine insemination. The women were given ovarian stimulation with tab letrozole and injectable gonadotropins. Transvaginal ultrasound for folliculometry was done from day 8 onwards. When the leading follicle was at least 14 mm, the women were assigned into two groups. Elagolix 150 mg once daily was added and continued to the day of trigger in the intervention group. Patients in the control group did not receive elagolix as described above. Premature LH surge (serum LH≥10) and premature luteinization (serum LH≥10 IU/l and serum progesterone ≥1 ng/ml) were assessed on the day of trigger.

Results: Twenty-six women in the elagolix group and 26 in the control arm completed the study. There was total absence of premature LH surge and premature luteinization in the elagolix group as compared to the 30.8% and 23.1% respectively in the control group. There was no statistically significant difference in clinical pregnancy rates.

Conclusions: Elagolix, an oral GnRH antagonist, when applied to controlled ovarian stimulation for intrauterine insemination, eliminate premature luteal surge and premature luteinization. But there is no improvement in clinical pregnancy rate.

Metrics

Metrics Loading ...

References

Cohlem BJ. Should we continue performing intrauterine inseminations in the year 2004? Gynecol Obstet Invest. 2005;59:3-13.

Cantineau AE, Cohlem BJ. Dutch IUI study group. The prevalence and influence of LH surges in stimulated cycles combined with IUI during a prospective cohort study. Fertil Steril. 2007;88:107-12.

Coccia ME, Comparatto C, Bracco GL, Scarselly G. GnRH antagonist. Eur J Obstet Gynaecol Reprod Biol. 2004;115(Supp1):S44-S56.

Bakas P, Konidaris S, Liapis A, Gregoriou O, Tzanakaki D, Creatsas G. Role of gonadotropin-releasing hormone antagonist in the management of sub- fertile couples with intrauterine insemination and controlled ovarian stimulation. Fertil Steril. 2011;95:2024-8.

Marviel P, Heraud MH, Grenier N, Lourdel E, San Guinet P, Copin H. Predictive factors for pregnancy after intrauterine insemination (IUI): an analysis of 1038 cycles and a review of the literature. Fertil Steril. 2010;93:79-88.

Martinez-Salazar J, Cerrillo M, Quea G, Pacheco A, Garcia-Velasco JA. GnRH antagonist ganirelix prevents premature luteinization in IUI cycles: rationale for its use. Reprod Biomed Online. 2009;19:156-61.

Marci R, Caserta D, Lisi F, Graziano A, Soave I, Lo Monte G, et al. In vitro fertilization stimulation protocol for normal responder patients. Gynecol Endocrinol. 2013;29(2):109-12.

Gomez-Palomares JL, Acevedo-Martin B, Chavez M, Manzanares A, Ricciarelli E, Hernandez ER. Multifollicular recruitment in combination with gonadotrophin-releasing hormone antagonist increased pregnancy rates in intrauterine insemination cycles. Fertil Steril. 2007;89:620-4.

Steward RG, Gill I, Williams DB, Witz CA, Griffith J and Haddad GF. Cetrorelix lowers premature luteinization rate in gonadotropin ovulation induction intrauterine insemination cycles: a randomized-controlled clinical trial. Fertil Steril. 2010;95:434-6.

Shebley M, Polepally AR, Nader A, Ng JW, Winzenborg I, Klein CE, et al. Clinical pharmacology of elagolix: an oral gonadotropin-releasing hormone receptor antagonist for endometriosis. Clin Pharmacokinet. 2020;59(3):297-309.

Ng J, Chwalisz K, Carter DC, Klein CE. Dose-dependent suppression of gonadotropins and ovarian hormones by elagolix in healthy premenopausal women. J Clin Endocrinol Metab. 2017;102(5):1683-91.

Boniface C, Schnorr J, Schnorr J, Slowey MJ, Cook H, McLaughlin J, et al. The role of elagolix in the suppression of ovulation in donor oocyte cycles. Fertil Steril. 2021;116(3):e36-7.

Komiya S, Tsuzuki-Nakao T, Asai Y, Inoue T, Morimoto Y, Okada H. The novel oral gonadotropin-releasing hormone receptor antagonist relugolix is a new option for controlled ovarian stimulation cycles. Reprod Med Biol. 2022;21:e12448.

Wadhwa L, Khanna R, Gupta T, Gupta S, Arora S, Nandwani S. Evaluation of role of GnRH antagonist in intrauterine insemination (IUI) cycles with mild ovarian hyperstimulation (MOH): a prospective randomised study. J Obstet Gynecol India. 2016;66(1):459-65.

Kamath MS, Ramya R, Bhave P, Muthukumar K, Aleyamma TK, George K. Effectiveness of GnRH antagonist in intrauterine insemination cycles. Eur J Obstet Gynecol Reprod Biol. 2013;166(2):168-72.

Lee TH, Lin YH, Seow KM, Hwang JL, Tzeng CR, Yang YS. Effectiveness of cetrorelix for the prevention of premature luteinizing hormone surge during controlled ovarian stimulation using letrozole and gonadotropins: a randomized trial. Fertil Steril. 2008;90(1):113-20.

Allegra A, Marino A, Coffaro F, Scaglione P, Sammartano F, Rizza G, et al. GnRH antagonist-induced inhibition of the premature LH surge increases pregnancy rates in IUI-stimulated cycles. A prospective randomized trial. Hum Reprod. 2007;22(1):101-8.

Lambalk CB, Leader A, Olivennes F, Fluker MR, Andersen AN, Ingerslev J, et al. Treatment with the GnRH antagonist ganirelix prevents premature LH rises and luteinization in stimulated intrauterine insemination: results of a double-blind, placebo-controlled, multicentre trial. Hum Reprod. 2006;21(3):632-9.

Graziano A, Caserta D, Piva I, LO Monte G, Bordi G, Martini F, et al. The addition of GnRH antagonists in intrauterine insemination cycles: a pilot study. Eur Rev Med Pharmacol Sci. 2013;17(12):1604-10.

Checa MA, Prat M, Robles A, Carreras R. Use of gonadotropin-releasing hormone antagonists to overcome the drawbacks of intrauterine insemination on weekends. Fertil Steril. 2006;85(3):573-7.

Vitagliano A, Saccone G, Noventa M, Borini A, Coccia ME, Nardelli GB, et al. Pituitary block with gonadotrophin‐releasing hormone antagonist during intrauterine insemination cycles: a systematic review and meta‐analysis of randomised controlled trials. BJOG. 2019;126(2):167-75.